托伐普坦在常染色体显性多囊肾病中的长期给药
本研究在Mayo Clinic对97例接受托伐普坦≥1年的常染色体显性多囊肾病(ADPKD)患者进行疗效分析,并与匹配对照比较。结果显示托伐普坦组eGFR下降斜率显著低于对照组,且eGFR下降33%的风险更低,提示长期治疗可持续减缓肾功能下降。
要点
- 托伐普坦长期治疗可持续减缓ADPKD患者eGFR下降速率。
- 治疗组eGFR下降33%的风险显著低于匹配对照组。
- eGFR获益随治疗时间延长而累积,两组差异逐渐增大。
核心结论
- 随访长达11.2年(平均4.6年)显示,托伐普坦治疗组eGFR年下降率持续低于对照组,且两组eGFR差异随时间增大。
主要发现
- 托伐普坦组从基线eGFR斜率(均值±SD)为-2.20±2.18 ml/min per 1.73 m2 per year,从第1个月为-1.97±2.44 ml/min per 1.73 m2 per year,均低于对照组(-3.50±2.09 ml/min per 1.73 m2 per year;P<0.001)。
- 托伐普坦组eGFR下降33%的风险比从基线为0.63(95%CI 0.38至0.98),从第1个月为0.53(95%CI 0.31至0.85)。
- 托伐普坦治疗患者的年化eGFR斜率在随访期间无变化,末次随访时观察与预测eGFR的差异随治疗时间延长而增大。
临床怎么用
- 对于ADPKD患者,长期使用托伐普坦可考虑用于减缓eGFR下降和降低eGFR显著下降风险,需结合患者具体情况评估。
局限性
- 本研究为单中心观察性分析,样本量有限(97例疗效分析),且非随机对照设计,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One hundred and twenty-eight patients with autosomal dominant polycystic kidney disease participated in clinical trials of tolvaptan at the Mayo Clinic. All had the opportunity to enroll into open-label extension studies. Twenty participated in short-term studies or received placebo only. The remaining 108 were analyzed for safety. Ninety seven patients treated with tolvaptan for ≥1 year (mean±SD, 4.6±2.8; range, 1.1-11.2) were analyzed for efficacy using three approaches: (1) comparison of eGFR slopes and outcome (33% reduction from baseline eGFR) to controls matched by sex, age, and baseline eGFR; (2) Stability of eGFR slopes with duration of follow-up; and (3) comparison of observed and predicted eGFRs at last follow-up. RESULTS: Patients treated with tolvaptan had lower eGFR slopes from baseline (mean±SD, -2.20±2.18 ml/min per 1.73 m2 per year) and from month 1 (mean±SD, -1.97±2.44 ml/min per 1.73 m2 per year) compared with controls (mean±SD, -3.50±2.09 ml/min per 1.73 m2 per year; P<0.001), and lower risk of a 33% reduction in eGFR (risk ratio, 0.63; 95% confidence interval, 0.38 to 0.98 from baseline; risk ratio, 0.53; 95% confidence interval, 0.31 to 0.85 from month 1). Annualized eGFR slopes of patients treated with tolvaptan did not change during follow-up and differences between observed and predicted eGFRs at last follow-up increased with duration of treatment. CONCLUSIONS: Follow-up for up to 11.2 years (average 4.6 years) showed a sustained reduction in the annual rate of eGFR decline in patients treated with tolvaptan compared with controls and an increasing separation of eGFR values over time between the two groups.
引用
- Edwards ME, Chebib FT, Irazabal MV, et al. Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018. PMID: 30026287. doi:10.2215/CJN.01520218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。